ភាគហ៊ុនជីវបច្ចេកវិទ្យា និងឱសថឈានមុខគេ ខណៈឆ្នាំ 2022 ខិតជិតមកដល់

A handful of biotech and medical stocks have joined the elite IBD 50 list, boasting strong fundamentals and high growth potential. These leading industry groups have proven winners booking double-digit returns in 2022.

X

ហ្គេមម៉ាប (GMAB) was added to the IBD 50 Top 10 list this week. Medpace (MEDP) was also added to this list and IBD’s តារាង. Other top performers include ឱសថកាតាលីករ (ក្រុមហ៊ុន CPRX) និង Inspire Medical (INSP).

The biotech and medical stock sectors started to decline in February 2021 and hit new lows this summer. They bounded with a steady run through August and pulled back, trading sideways into year’s end. These groups are seen as defensive plays and a good place for investors to park their cash.

One Stock Extended, Another Should Be Cashed In

Catalyst is extended from the តំបន់ទិញ 5% នៃ មូលដ្ឋានពែងជាមួយចំណុចទាញ ជាមួយ ចំណុចទិញ of 16.76. The rare disease drugmaker produced accelerating EPS and sales growth in the last three quarters.

The stock has been trending upward since a positive Q3 earnings report in early November. Shares have risen an impressive 180% year to date.

Analysts expect annual EPS growth of 33% in 2022 and 66% in 2023. Catalyst is first in the 800 strong Medical-Biomed/Biotech industry group, which is ranked 30th out of the 197 IBD stocks.

Medpace is trying to form a new consolidating មូលដ្ឋាន after breaking out of a cup pattern following ប្រសើរជាងការរំពឹងទុក Q3 earnings and sales numbers late October. The biotech specializes in research for drug and medical devices, and clinical trial management. The stock pulled back and has been in volatile trading since the breakout.

Inspire Medical is in the តំបន់ប្រាក់ចំណេញ 20% ទៅ 25% after hitting the 212.22 buy point of a មូលដ្ឋានបាតទ្វេ. ភាគហ៊ុន បានផ្ទុះឡើង after reporting a smaller Q3 loss and higher than expected sales on Nov. 1.

The company produces the only FDA-approved implanted sleep apnea device. Inspire is yet to be profitable.

Inspire has shown consistent quarterly sales growth in the 70% range for the last five quarters.

Mutual funds own 77% of INSP shares, with 580 owning shares in September, up from 565 in June and 542 in March.

Other Hot Biotech And Medical Stocks

Denmark-based biotech and medical stock Genmab has shown accelerating quarterly growth in sales and EPS.

Shares of this cancer drugmaker emerged from a long, deep មូលដ្ឋានពែង after a failed attempt at a proper handle. GMAB dropped below its មធ្យមចលនាអិចស្ប៉ូណង់ស្យែលរយៈពេល ២១ ថ្ងៃ and touched the 50 ថ្ងៃនៃការផ្លាស់ប្តូរជាមធ្យម, finding support at the line.

AstraZeneca ។ (AZN) pulled back after breaking out of a double-bottom base in December. Shares took a dive on news the company’s prostate cancer drug will face an extended review by the Food and Drug Association.

ជាចុងក្រោយ, ជីវវិទ្យាវិទ្យាសាស្ត្រប្រសាទ (អិនប៊ីស៊ី) makes neurological and endocrine-related disease treatments, and is up almost 41% year to date.

អ្នកអាចចូលចិត្តបានផងដែរ៖
ទទួលបានព្រឹត្តិប័ត្រព័ត៌មាន IBD ដោយឥតគិតថ្លៃ: Prep Market | របាយការណ៍បច្ចេកវិទ្យា | វិធីវិនិយោគ

តើស៊ីអិនអិម SLIM គឺជាអ្វី? ប្រសិនបើអ្នកចង់ស្វែងរកភាគហ៊ុនដែលឈ្នះសូមស្គាល់វាកាន់តែច្បាស់

អាយ។ អេស។ បន្តផ្ទាល់៖ រៀននិងវិភាគភាគហ៊ុនកំណើនជាមួយប្រុស

ឧបករណ៍របស់ MarketSmith អាចជួយវិនិយោគិនម្នាក់ៗ

កំពុងស្វែងរកអ្នកឈ្នះទីផ្សារភាគហ៊ុនធំបន្ទាប់? ចាប់ផ្តើមជាមួយជំហ៊ានទាំង ៣ នេះ